EQS-Adhoc: Evolva secures additional financing lines to accelerate its growth

0

EQS-Ad-hoc: Evolva Holding SA / Keyword (s): Financing
Evolva secures additional financing lines to accelerate its growth

27-Dec-2021 / 07:00 CET / CEST
Publication of an ad hoc announcement in accordance with art. 53 LR
The sender is solely responsible for the content of this advertisement.


Reinach, December 27, 2021 – Evolva (SIX: EVE), the Swiss biotechnology company focused on the research, development and commercialization of nature-based products, today signed an agreement with Nice & Green, a Swiss investment company, to secure additional financing lines until the end of 2023.

Funding lines can be drawn by Evolva in quarterly installments as needed to support business activities and product launches in key markets (pending regulatory approvals), to leverage manufacturing efficiency and to expand manufacturing capacity, as well as to finance further development of the company’s product. pipeline.

Under the agreement, Nice & Green is committed to providing additional financing lines in the form of convertible notes under agreed terms up to a maximum principal amount of CHF 12 million until the end of 2023. With the Currently unused funding line of CHF 16 million, Evolva has funding lines totaling CHF 28 million available, if required. The principal amount of each convertible note is, at Evolva’s discretion, either redeemable by way of conversion into ordinary shares of the company or in cash. The conversion price is 95 percent of the lowest daily volume weighted average price for a share on the SIX Swiss Exchange during the 6 trading days immediately preceding the conversion.

About Evolva
Evolva is a Swiss biotechnology company focused on the research, development and commercialization of nature-based ingredients. We have leading activities in the fields of aromas and fragrances, health ingredients and health protection. Evolva employees, half of whom are women, are dedicated to making the best products that can contribute to health, well-being and sensory pleasure. Learn more about evolva.com and connect with us on LinkedIn.

Warning
This press release contains specific forward-looking statements, for example statements that include words such as believe, assume, expect or similar expressions. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may cause the actual results, financial position, development or performance of the company to differ materially from those explicitly or implicitly assumed in these statements. statements. In the context of these uncertainties, readers should not place undue reliance on forward-looking statements. The company assumes no responsibility for updating forward-looking statements or their adaptation to future events or developments.

Contact
Thomas Schneckenburger
Investor and corporate relations
+41 61 485 2003
+41 79 407 9952
[email protected]


End of ad hoc announcement


Share this news on your Fb, Twitter and Whatsapp

File source

News Nation USA: Latest news headlines
USA Nation News || USA News || Science || Education || Sports || World

Share.

About Author

Comments are closed.